• Jade Biosciences appointed Mark Eisner to its board, effective June 25, 2026.
• Eisner most recently served as executive vice president and chief medical officer at Vir Biotechnology.
• He previously held chief medical officer roles at Sonoma Biotherapeutics, FibroGen, and spent nearly 11 years at Genentech/Roche in product development leadership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606260700PRIMZONEFULLFEED9752661) on June 26, 2026, and is solely responsible for the information contained therein.